2026-W46 · Nov 9–Nov 15 · Company · Profile · published
Insulet Corporation company profile · business segments · history · financial snapshot · S&P 500 rank #488 · Insulet公司業務歷史財務與標普500地位
SNAPSHOT
| Ticker | PODD |
| Company | Insulet Corporation |
| GICS sector / industry | Health Care (XLV) / Health Care Equipment |
| S&P 500 rank (by weight) | #488 · 0.02% (Nov 5, 2026) |
| Sector rank | #59 of 60 in Health Care (Nov 5, 2026) |
| Headquarters | Acton, Massachusetts |
| Founded | 2000 |
| CEO | Ashley McEvoy (President and Chief Executive Officer) |
| Employees | ~5,400 (as of December 31, 2025) |
| Market cap | $11.16B (Nov 5, 2026) |
| SEC filings | EDGAR — CIK 1145197 |
WHAT IT DOES
Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, built around one product platform: Omnipod, a tubeless, disposable insulin pump worn directly on the body. Its Omnipod 5 system automates insulin delivery using readings from a continuous glucose monitor, serving people with type 1 and type 2 diabetes, mainly in the United States and increasingly in international markets.
Its one-line model: sell the wearable Pod as a recurring consumable through pharmacy and distributor channels, so revenue repeats with every Pod change rather than depending on a one-off device sale. Fiscal 2025 revenue was $2,708.1M, of which Omnipod products were $2,674.0M.
BUSINESS SEGMENTS
| Single reportable segment — Omnipod platform | Insulet operates in one reportable segment. Fiscal 2025 revenue by product: Omnipod products $2,674.0M and Drug Delivery $34.1M; by customer location, United States $1,953.9M and International $754.3M. |
HISTORY
| Year | Milestone |
|---|---|
| 2000 | Insulet is founded in Massachusetts to develop a tubeless, wearable insulin delivery system — the Omnipod platform. |
| 2005 | The first Omnipod insulin management system reaches the market, replacing tubed pumps with a disposable wearable Pod. |
| 2007 | Insulet completes its initial public offering and lists on Nasdaq. |
| 2022 | The FDA clears Omnipod 5, the company's automated insulin delivery system integrating continuous glucose monitoring. |
| 2025 | Ashley McEvoy becomes President and CEO in April 2025, succeeding James Hollingshead; revenue reaches $2,708.1M in fiscal 2025. |
COMPETITIVE POSITION
FINANCIAL SNAPSHOT
| Total revenue | $2.71B (FY2025 revenue) |
| Operating income | $473.8M (FY2025 operating income) |
| Net income | $247.1M (FY2025 net income) |
| Diluted EPS | $3.48 (FY2025 diluted EPS) |
KEY RISKS
WHY IT MATTERS FOR THE S&P 500
Insulet is a small-weight Health Care constituent: rank #488 by weight at 0.02% as of Nov 5, 2026, and #59 in Health Care. It matters as the index's pure-play exposure to automated insulin delivery — a device category still penetrating the large type 2 diabetes population, where adoption, not market size, is the constraint.
SOURCES & METHODOLOGY
| Financials, segments, headquarters | Insulet Corporation fiscal 2025 Form 10-K via SEC EDGAR (see Financial Snapshot note); headquarters, CEO and history via the Form 10-K and Wikipedia company profile |
| Index weight & ranks | Slickcharts S&P 500 weights, fetched Nov 5, 2026; sector membership per Wikipedia List of S&P 500 companies (GICS) |
| Market cap | $11.16B (Slickcharts, Nov 5, 2026) |
| Logo | SPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics. |
| Chart | SPXSet chart library, monthly bars, compiled from Yahoo public information. |
Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com
FINANCIALS
公司快照
| 股票代號 | PODD |
| 公司 | Insulet Corporation(Insulet) |
| GICS 板塊/行業 | 健康護理(XLV)/醫療設備 |
| 標普500排名(按權重) | #488 · 0.02%(Nov 5, 2026) |
| 板塊內排名 | 健康護理板塊 #59(共 60 家)(Nov 5, 2026) |
| 總部 | 美國麻薩諸塞州阿克頓 |
| 成立 | 2000年 |
| 執行長 | Ashley McEvoy(總裁兼執行長) |
| 員工 | 約5,400人(截至2025年12月31日) |
| 市值 | $11.16B(Nov 5, 2026) |
| SEC 申報 | EDGAR — CIK 1145197 |
業務概覽
Insulet Corporation 是總部位於麻薩諸塞州阿克頓的醫療設備公司,業務圍繞單一產品平台:Omnipod — 直接佩戴在身上的無管一次性胰島素泵。其 Omnipod 5 系統利用連續血糖監測讀數自動遞送胰島素,服務第一型及第二型糖尿病患者,主要市場在美國,國際市場佔比正提升。
其一句話商業模式是:透過藥房與分銷渠道把可穿戴 Pod 作為經常性消耗品銷售,收入隨每次更換 Pod 重複產生,而非依賴一次性設備銷售。2025 財年收入為 27.081 億美元,其中 Omnipod 產品佔 26.740 億美元。
業務板塊
| 單一可呈報板塊 — Omnipod 平台 | Insulet 以單一可呈報板塊營運。2025 財年收入按產品劃分:Omnipod 產品 26.740 億美元、藥物遞送 3,410 萬美元;按客戶所在地劃分:美國 19.539 億美元、國際 7.543 億美元。 |
歷史
| 年份 | 里程碑 |
|---|---|
| 2000 | Insulet 在麻薩諸塞州成立,開發無管、可穿戴的胰島素遞送系統 — Omnipod 平台。 |
| 2005 | 首個 Omnipod 胰島素管理系統推出市場,以一次性可穿戴 Pod 取代有管泵。 |
| 2007 | Insulet 完成首次公開招股,在納斯達克上市。 |
| 2022 | 美國食品藥物管理局核准 Omnipod 5 — 結合連續血糖監測的自動胰島素遞送系統。 |
| 2025 | Ashley McEvoy 於 2025 年 4 月出任總裁兼執行長,接替 James Hollingshead;2025 財年收入達 27.081 億美元。 |
競爭地位
財務快照
| 總收入 | 27.08 億美元(2025 財年收入) |
| 營業利潤 | 4.74 億美元(2025 財年營業利潤) |
| 淨利潤 | 2.47 億美元(2025 財年淨利潤) |
| 稀釋 EPS | 3.48 美元(2025 財年稀釋 EPS) |
主要風險
對標普500的重要性
Insulet 是權重較小的健康護理成分股:截至 2026 年 11 月 5 日按權重排名第 488 位,權重 0.02%,在健康護理板塊排第 59 位。其重要性在於它是標普 500 中專注自動胰島素遞送的代表 — 該設備品類正滲透龐大的第二型糖尿病群體,限制因素是採用率而非市場規模。
來源與方法
| 財務、板塊、總部 | Insulet Corporation 2025 財年 Form 10-K,經 SEC EDGAR(見財務快照附註);總部、執行長與歷史經 Form 10-K 及維基百科公司簡介核對 |
| 指數權重與排名 | Slickcharts 標普 500 權重,Nov 5, 2026 抓取;板塊歸屬按維基百科標普 500 成分股名單(GICS) |
| 市值 | $11.16B(Slickcharts,Nov 5, 2026) |
| Logo | SPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。 |
| 股價圖 | SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。 |
來源:Yahoo Finance 月線(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份)· SPXSet.com
財報
SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。
Entered 2026-11-04 14:49 · updated 2026-11-14 23:56 · rev 6